Meghan Karuturi

Meghan Karuturi is an Associate Professor at The University of Texas MD Anderson Cancer Center. Her research focuses on breast oncology, specifically the management of advanced hormone receptor-positive/HER2-negative disease, geriatric oncology, and quality-of-life outcomes in cancer survivorship. She leads investigations into CDK4/6 inhibitor therapies, such as palbociclib, examining real-world efficacy, circulating tumor DNA biomarkers, and the impact of comorbidities on patient outcomes. Her recent work also adapts patient priorities care approaches to improve survivorship care for older adults with early-stage triple-negative breast cancer. She has published extensively in venues including *JCO Precision Oncology*, *The Oncologist*, and the *Journal of Geriatric Oncology*, contributing to both clinical trial analyses and patient-centered implementation strategies.